Medtronic plc (NYSE:MDT) 2024 Barclays 26th Annual Healthcare Conference Call March 12, 2024 8:00 AM ET Company Participants Karen Parkhill - CFO Conference Call Participants Matt Miksic - Barclays Matt Miksic Good morning. Thanks so much for joining us. My name is Matt Miksic, I’m US Medical Device Analyst here at Barclays, and we are very pleased to have with us today Medtronic, specifically, CFO, Karen Parkhill, so thanks again so much for joining us. Karen Parkhill Thank you, Matt. Great to be here. Mat ...

Medtronic plc (MDT) is likely to grow in the coming quarters, backed by remarkable progress within the Cardiovascular portfolio. The Cranial and Spinal technologies business within the company’s Neuroscience portfolio has been registering strong growth in recent quarters. Favorable solvency is highly encouraging. Meanwhile, macroeconomic challenges may have an adverse impact on the company’s operations. Intense competition from peers is also concerning. In the past year, this Zacks Rank #3 (Hold) stock has ...

Just_Super/iStock via Getty Images Medtronic PLC (NYSE:MDT) is a global developer and manufacturer of medical devices for chronic diseases. Founded in 1949, Medtronic is now a $111 billion (by market cap) healthcare behemoth that employs 95,000 people. The company reports results across four segments: Cardiovascular, 37% of FY 2023 revenue; Neuroscience, 29%; Medical Surgical, 27%; and Diabetes, 7%. Medtronic’s product portfolio is comprised of a variety of life-saving and life-improving medical devices tha ...

Medtronic plc (MDT) recently presented a set of new clinical and real-world evidence on the MiniMed 780G system from around the world. The latest data reveals that the system withstands strong global performance, exceeding international targets for diabetes management. The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy. Study Details According to the business, the findings are built on three years of data published in Di ...

Key Points Medtronic is a leading medical device maker known for inventing the world's first portable and implantable pacemaker. Medtronic is a Dividend Aristocrat that's consistently raised its dividend payments for 46 consecutive years. Medtronic beat its fiscal Q3 2024 EPS by 15 cents, grew revenues by 4.7% YoY and raised its fiscal full-year 2024 guidance along with adding $5 billion to its stock buyback program. 5 stocks we like better than Medtronic Medical device maker Medtronic PLC NYSE: MDT is a Di ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th Internati ...

Board authorizes $5 billion for share repurchases DUBLIN, March 7, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 ...

Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no significant changes in stroke volume or contractility. AVIM therapy showed consistent favorable hemodynamic effects using both conduction system pacing, as well as traditional rig ...

Rising tides don't always lift all boats. The S&P 500 index reached new all-time highs several times since 2024 began, but many of its components have not participated in the rally. With most investors focusing all their attention on the artificial intelligence (AI) revolution, plenty of reliable dividend payers aren't getting the attention they deserve. Since peaking in 2021, shares of Medtronic (MDT 1.75%) are down about 38% and poised for a rebound. Altria Group (MO -2.77%) and Realty Income (O 0.90%) hi ...

This photo taken on Nov. 8, 2023 shows a booth of Medtronic at the 6th China International Import ... [+] Expo CIIE in east China's Shanghai. (Photo by Wang Xiang/Xinhua via Getty Images) Xinhua News Agency via Getty Images Medtronic MDT (NYSE: MDT) recently reported its Q3 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating the street estimates. The company reported revenue of $8.1 billion and adjusted earnings of $1.30 per share compared to the consensus estimates of $7.9 billio ...